Last reviewed · How we verify
ERITORAN
ERITORAN is a drug. It is currently in Phase 3 development.
ERITORAN works by binding to Toll-like receptor 4, a protein involved in the immune response.
ERITORAN is a small molecule modality targeting Toll-like receptor 4, but its drug class is unknown. Its commercial status is unclear, and it has not been approved by the FDA. The half-life of ERITORAN is approximately 51 hours. Further information on its bioavailability, generic manufacturers, and off-patent status is not available. As a result, its approved indications and safety considerations are also unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ERITORAN |
|---|---|
| Target | Toll-like receptor 4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Think of Toll-like receptor 4 like a security guard that recognizes and responds to potential threats, such as bacteria or viruses. ERITORAN acts like a key that blocks the security guard from sending out an alarm, which can help reduce inflammation and other immune responses. This can be beneficial in treating conditions where the immune system is overactive.
Approved indications
Common side effects
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects (PHASE2)
- The Role of TLR4 on Lipid-induced Insulin Resistance (PHASE2)
- ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis (PHASE3)
- A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ERITORAN CI brief — competitive landscape report
- ERITORAN updates RSS · CI watch RSS
Frequently asked questions about ERITORAN
What is ERITORAN?
How does ERITORAN work?
What development phase is ERITORAN in?
What does ERITORAN target?
Related
- Target: All drugs targeting Toll-like receptor 4
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing